Skip to main content

Table 2 Comparison of AMBITION cohort with healthy controls in patient demographics and baseline biomarker levels. Differences between cohorts are shown as ANCOVA values adjusted for race differences

From: Connective tissue remodelling is differently modulated by tocilizumab versus methotrexate monotherapy in patients with early rheumatoid arthritis: the AMBITION study

Variables

AMBITION cohort RA patients (N = 387)

Healthy controls (N = 72)

Difference between cohorts

Age (years), mean (SD)

50.9 (12.9)

49.7 (6.1)

ns

Female, n (%)

300 (76)

41 (76)

ns

Race, no. white/black/other (%)

325 (84)/14 (4)/48 (12)

51 (71)/21 (29)/0 (0)

< 0.0001

Baseline C1M (ng/mL), mean (SD)

43.4 (30.7)

18.7 (15.3)

< 0.001

Baseline C2M (ng/mL), mean (SD)

0.38 (0.2)

0.3 (0.16)

< 0.001

Baseline C3M (ng/mL), mean (SD)

17.8 (8.0)

11.1 (2.8)

< 0.001

Baseline C4M (ng/mL), mean (SD)

50.9 (24.9)

21.5 (6.1)

< 0.001

Baseline CRPM (ng/mL), mean (SD)

20.9 (12.9)

7.5 (2.1)

< 0.001

Baseline CRP (ng/mL), mean (SD)

3.0 (3.5)